[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Smith & Nephew Snats ADR (SNN)

Smith & Nephew Snats ADR (SNN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,303,919
  • Shares Outstanding, K 419,929
  • Annual Sales, $ 6,164 M
  • Annual Income, $ 625,000 K
  • EBIT $ 0 M
  • EBITDA $ 1,367 M
  • 60-Month Beta 0.55
  • Price/Sales 1.99
  • Price/Cash Flow 8.52
  • Price/Book 2.38

Options Overview Details

View History
  • Implied Volatility 34.02% (-7.53%)
  • Historical Volatility 29.30%
  • IV Percentile 5%
  • IV Rank 7.56%
  • IV High 123.13% on 01/12/26
  • IV Low 26.73% on 08/17/26
  • Expected Move (DTE 21) 0.38 (1.31%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 11
  • Volume Avg (30-Day) 1,256
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 132
  • Open Int (30-Day) 16,430
  • Expected Range 28.75 to 29.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.71 +1.46%
on 08/21/26
32.92 -11.50%
on 08/03/26
-1.99 (-6.39%)
since 07/27/26
3-Month
28.56 +2.01%
on 06/30/26
32.92 -11.50%
on 08/03/26
-1.08 (-3.57%)
since 05/27/26
52-Week
28.56 +2.01%
on 06/30/26
38.79 -24.90%
on 09/09/25
-8.12 (-21.80%)
since 08/27/25

Most Recent Stories

More News
Smith+Nephew and Imperial College London launch centre to accelerate innovation in surgical robotics

Smith+Nephew and Imperial College London launch centre to accelerate innovation in surgical robotics

SNN : 29.13 (-0.58%)
Smith+Nephew’s new FLOW FLEXTEND™ COBLATION™ Wand improves access¹* and resection efficiency²** for complex hip procedures vs. fixed-angle options

Smith+Nephew’s new FLOW FLEXTEND™ COBLATION™ Wand improves access¹* and resection efficiency²** for complex hip procedures vs. fixed-angle options

SNN : 29.13 (-0.58%)
Smith+Nephew celebrates mobility, recovery and football's greatest traditions during Pro Football Hall of Fame Enshrinement Week

Smith+Nephew will host a series of engagement opportunities during the 2026 Pro Football Hall of Fame Enshrinement Week in Canton, Ohio....

SNN : 29.13 (-0.58%)
Smith+Nephew’s TESSA™ Spatial Surgery System granted De Novo classification by the FDA sparking a generational leap in Sports Medicine for personalized planning and procedural innovation

Smith+Nephew’s TESSA Spatial Surgery System granted De Novo classification by the FDA; a generational leap in Sports Medicine for personalized planning ...

SNN : 29.13 (-0.58%)
Smith+Nephew introduces expanded enterprise ASC Solutions Strategy to support growth, performance and value-based care

Smith+Nephew introduces expanded enterprise ASC Solutions Strategy to support growth, performance and value-based care ...

SNN : 29.13 (-0.58%)
Smith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impact

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the US launch of next generation LEAF♢ Patient Monitoring System, a...

SNN : 29.13 (-0.58%)
Smith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading...

SNN : 29.13 (-0.58%)
Smith+Nephew launches next-generation ALLEVYN™ COMPLETE CARE Foam Dressing - designed for high performance in wound management and pressure injury prevention

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, recently announced the launch of ALLEVYN♢ COMPLETE CARE Foam Dressing, featuring...

SNN : 29.13 (-0.58%)
Smith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026

Smith+Nephew announces it will feature handheld robotics during the American Academy of Orthopedic Surgeons (AAOS) Annual meeting in New Orleans this...

SNN : 29.13 (-0.58%)
Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026

Smith+Nephew will showcase its unrivalled rotator cuff repair portfolio, including Tendon Seam and REGENETEN, at AAOS 2026 in New Orleans this week....

SNN : 29.13 (-0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative...

See More

Key Turning Points

3rd Resistance Point 29.60
2nd Resistance Point 29.47
1st Resistance Point 29.30
Last Price 29.13
1st Support Level 29.00
2nd Support Level 28.87
3rd Support Level 28.70

See More

52-Week High 38.79
Fibonacci 61.8% 34.88
Fibonacci 50% 33.67
Fibonacci 38.2% 32.46
Last Price 29.13
52-Week Low 28.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.